ANIP
ANI Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -20.0% ·
share flow +20.8% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 102 | +1 | 15.27M | $1.21B | +7 | −5 |
| Q1 2026 | 103 | -4 | 30.24M | $1.11B | +4 | −9 |
| Q4 2025 | 108 | 0 | 15.43M | $1.15B | +1 | — |
| Q3 2025 | 20 | +5 | 7.92M | $725.10M | +5 | −1 |
| Q2 2025 | 13 | -1 | 6.82M | $445.05M | — | −1 |
| Q1 2025 | 11 | +3 | 3.19M | $213.52M | +3 | — |
| Q4 2024 | 8 | -2 | 3.16M | $174.48M | — | −2 |
| Q3 2024 | 9 | -3 | 1.88M | $111.88M | — | −3 |
| Q2 2024 | 12 | — | 1.26M | $80.52M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 1.00M | +89.3% | $55.44M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 737.29K | — | $40.76M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 591.59K | +11.7% | $32.70M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 591.59K | +11.7% | $32.70M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 429.00K | +0.9% | $23.72M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 429.00K | +0.9% | $23.72M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 196.32K | +80.7% | $10.85M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 175.80K | -28.3% | $9.72M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 16.09K | +4.5% | $889,621 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 16.09K | +4.5% | $889,621 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 16.09K | +4.5% | $889,621 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 7.29K | +20.1% | $403,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Wellington Management | $561,461 | was 0.0% |
| Two Sigma Investments | $340,420 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 276 holders, 23.08M shares, $1.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 500 sh · $37,740
Officer · 3.16K sh · $243,474
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology